SCOTTSDALE, Ariz. — Aug. 11, 2026 — Physicians at HonorHealth Research Institute have begun testing a personalized dendritic-cell vaccine designed to treat advanced melanoma that has stopped responding to available therapies. The investigational product, DOC1021, also known as dubodencel, is being evaluated in patients whose tumors are refractory and either unresectable or metastatic. The study is among a limited number of sites in the United States offering this approach, which aims to redirect the immune system against an individual patient’s cancer.
Melanoma develops from melanocytes, the pigment-producing cells that help protect tissues from ultraviolet radiation. Although most melanomas begin in the skin, the disease can also arise in mucosal tissues lining structures such as the ears, nose, lungs, mouth and digestive tract. Once melanoma spreads to distant organs or becomes resistant to immune checkpoint inhibitors and other treatments, therapeutic options can be limited. The new trial is therefore focused on a group of patients with particularly aggressive disease and a high unmet medical need.
DOC1021 is built around dendritic cells, specialized antigen-presenting cells that coordinate the immune response. Dendritic cells collect molecular information from foreign organisms or abnormal cells and display fragments of that material to T cells, helping determine what the immune system should attack. In the investigational treatment, a patient’s dendritic cells are combined with messenger RNA, or mRNA, and proteins derived from a biopsy of the patient’s tumor. The resulting cellular product is intended to present multiple cancer-associated signals to the immune system rather than relying on a single target.
“The vaccine trains the immune cells to recognize the cancer as if it were an infection,” said Justin Moser, M.D., the trial’s principal investigator and an associate clinical investigator in HonorHealth Research Institute’s Oncology Research Division. Moser, who specializes in melanoma, said conventional cancer vaccines have often produced immune responses that were not powerful or durable enough to control metastatic disease. The trial will test whether the personalized formulation can overcome some of those limitations in patients whose melanoma has resisted standard care.
The treatment’s design is based on the principle that tumors can evade immune surveillance by suppressing immune cells, altering the proteins displayed on their surfaces or creating a hostile environment around the cancer. By loading dendritic cells with both tumor-derived mRNA and proteins, researchers seek to provide the immune system with a broader set of instructions for identifying malignant cells. Joseph Georges, D.O., Ph.D., a neurosurgeon at Scottsdale Neurosurgery Specialists, said the dual-loading strategy generated an immune response nearly ten times greater than approaches using only mRNA or only protein materials in the research underlying the technology. That comparison reflects the developers’ findings and remains subject to clinical validation in melanoma patients.
The vaccine platform was previously investigated in a clinical trial for glioblastoma, the most common primary malignant brain tumor in adults. Georges contributed to preclinical studies supporting that work. According to HonorHealth, some participants in the early phases survived more than two or three years without significant adverse effects, exceeding the approximately 15-month average survival often cited for glioblastoma. Those observations helped prompt research into whether the same immune-training strategy could be adapted for other cancers, including melanoma and pancreatic cancer.
The dendritic-cell vaccine differs from tumor-infiltrating lymphocyte, or TIL, therapy, another cellular treatment available through HonorHealth Research Institute. TIL therapy removes naturally occurring immune cells from a patient’s tumor, expands and strengthens them in a laboratory, and then returns billions of these cells to the patient. Because TILs already possess some ability to recognize the tumor, the treatment seeks to amplify an existing response. DOC1021 takes a different route: it attempts to teach the immune system to recognize the cancer by using dendritic cells as biological messengers that activate and direct T cells and B cells.
TIL treatment commonly involves preparative chemotherapy and additional medicines to support the infused immune cells. DOC1021 is intended to activate the patient’s own immune system without those additional treatments, according to the researchers. That distinction could affect how the therapy is administered and which patients may be able to receive it, although the safety, effectiveness and durability of the vaccine response will need to be established through the trial. As with any investigational therapy, early laboratory or preliminary clinical findings cannot yet demonstrate that the treatment will extend survival or provide lasting tumor control.
The trial, titled “Dendritic Cell Immunotherapy for Refractory Melanoma,” is being conducted by HonorHealth Research Institute in collaboration with Diakonos Oncology, the Houston-based company developing DOC1021. Researchers will study the therapy in people with advanced melanoma that cannot be removed surgically or has spread to other organs after failing existing treatments. The research institute describes the study as a randomized controlled or clinical trial, but the announcement does not provide detailed information about the number of participants, treatment arms, eligibility criteria or primary endpoints. Those details will be important for interpreting the results as the study progresses.
The launch reflects a broader shift toward personalized immunotherapy, in which a patient’s tumor is used to generate treatment-specific molecular information. Cancer vaccines are intended not merely to stimulate immunity in general, but to focus immune cells on antigens that distinguish malignant tissue from healthy tissue. “Our immune system has the hardware to attack and kill cancer cells,” Georges said. “It’s just that cancers get really good at fooling our immune system.” By supplying immune cells with a more complete molecular portrait of a tumor, researchers hope to make that concealment more difficult. Whether DOC1021 can produce meaningful responses in treatment-resistant melanoma will depend on the outcomes of the ongoing clinical investigation.
Subject of Research: People
Article Title: Personalized Dendritic-Cell Vaccine Enters Clinical Trial for Treatment-Resistant Advanced Melanoma
News Publication Date: Aug. 11, 2026
Web References: www.honorhealthresearch.org
References: HonorHealth Research Institute; Diakonos Oncology; “Dendritic Cell Immunotherapy for Refractory Melanoma” clinical trial
Keywords: melanoma, advanced melanoma, cancer immunotherapy, dendritic cells, DOC1021, dubodencel, personalized cancer vaccine, mRNA, tumor proteins, clinical trial, metastatic cancer, refractory cancer, HonorHealth Research Institute
